sorafenib has been researched along with Liposarcoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Borden, E; Bramwell, V; Demetri, GD; Goldblum, JR; Rankin, C; Ryan, CW; von Mehren, M | 1 |
| Ambrosini, G; Cheema, HS; Sambol, EB; Schwartz, GK; Seelman, S; Singer, S; Teed, A | 1 |
1 trial(s) available for sorafenib and Liposarcoma
| Article | Year |
|---|---|
Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Female; Humans; Leiomyosarcoma; Liposarcoma; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Sarcoma; Sorafenib; Survival Rate; Vascular Neoplasms | 2012 |
1 other study(ies) available for sorafenib and Liposarcoma
| Article | Year |
|---|---|
Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.
Topics: Antineoplastic Agents; Apoptosis; Benzenesulfonates; Blotting, Western; Cell Differentiation; Cell Proliferation; Cyclin D1; Cyclin-Dependent Kinase 4; Extracellular Signal-Regulated MAP Kinases; Flow Cytometry; G1 Phase; Gene Silencing; Humans; Liposarcoma; Mitogen-Activated Protein Kinase Kinases; Mitogen-Activated Protein Kinases; Nerve Sheath Neoplasms; Niacinamide; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-raf; Pyridines; ras Proteins; Retinoblastoma Protein; Signal Transduction; Sorafenib | 2008 |